Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 188 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2015  |  Volume : 5  |  Issue : 3  |  Page : 172-176

Association study of methylenetetrahydrofolate reductase A1298C mutation with cerebral venous thrombosis risk in an Iranian population

1 Cellular and Molecular Research Centre, Zahedan University of Medical Sciences, Zahedan, Iran
2 Department of Molecular Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
3 Iranian Blood Transfusion Organization, Tehran, Iran
4 Department of Laboratory Sciences, School of Paramedical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran

Correspondence Address:
Mohammad Soleiman Soltanpour
Department of Laboratory Sciences, School of Paramedical Sciences, Zanjan university of Medical Sciences, Zanjan
Login to access the Email id

Source of Support: Nill., Conflict of Interest: None declared.

DOI: 10.4103/2229-516X.165384

Rights and Permissions

Background: Cerebral venous thrombosis (CVT) is an uncommon condition characterized by severe clinical manifestations and high mortality rate. There is limited data on the role of methylenetetrahydrofolate reductase (MTHFR) A1298C mutation as a risk factor for CVT development in Iranians. Aim: The aim was to investigate a possible association between fasting plasma homocysteine (Hcy) levels, MTHFR A1298C mutation, and CVT in Iranian population. Materials and Methods: The study population consisted of 50 patients with a diagnosis of CVT (20–63 years old) and 75 healthy subjects (18–65 years old) as control. Genotyping of the MTHFR A1298C mutation and Hcy measurement was carried out by polymerase chain reaction-restriction fragment length polymorphism technique and enzyme immunoassay method, respectively. Results: Fasting plasma total Hcy levels were significantly higher in CVT patients than controls (P = 0.015). No significant differences were observed in the MTHFR A1298C genotypes frequency between CVT patients and controls (P > 0.05). The frequency of the 1298C allele was 36% and 37.5% in CVT patients and controls, respectively and did not differ significantly between the two groups (P = 0.16). Conclusions: Our study demonstrated that MTHFR A1298Cmutation is not a significant risk factor for CVT.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded306    
    Comments [Add]    
    Cited by others 1    

Recommend this journal